B
BioCircuit Technologies
Biotech & Life Sciences · Atlanta, United States · Founded 2016
Develops non-invasive electrophysiology devices which monitor, control, and repair peripheral nerves MoreLess
BioCircuit Technologies specializes in advanced nerve repair solutions, primarily through its flagship product, Nerve Tape. This innovative medical device is designed to repair peripheral nerve discontinuities more effectively than traditional microsutures. Nerve Tape is 2.6 times stronger and 4.8 times faster than conventional microsuture repairs, significantly reducing surgery time and improving patient outcomes. The company serves healthcare providers, particularly in the fields of neurosurgery and orthopedics, operating within the medical device market. BioCircuit Technologies generates revenue through the sale of Nerve Tape to hospitals, clinics, and surgical centers. The business model focuses on providing a superior alternative to existing nerve repair methods, thereby enhancing the efficiency and success rates of nerve surgeries.
Keywords: nerve repair, medical device, Nerve Tape, peripheral nerve, microsuture alternative, neurosurgery, orthopedics, healthcare, surgical innovation, patient outcomes.
Talent graph
BioCircuit Technologies's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on BioCircuit Technologies's cap table
Sourced from Dealroom's funding and investor records.



Global footprint
Where BioCircuit Technologies has talent and traffic
team presence
Market sentiment
What the market is saying about BioCircuit Technologies
An AI-synthesized read of the highest-engagement posts about BioCircuit Technologies on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioCircuit Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.